Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CLSA Favors CDMOs for Earnings Visibility, Top Picks WUXI APPTEC/ WUXI BIO/ PHARMARON
Recommend 5 Positive 11 Negative 4 |
||||
|
||||
|
As AI technology continues to develop, investors are shifting their focus from "AI enabling industries" to "AI disintermediating middlemen", CLSA said in a research report. For CRO/ CDMO, AI is expected to have a clearer net positive for integrated CRDMO platforms. In contrast, the internal adoption of AI by pharmaceutical companies may have mixed effects on specialized CROs. Therefore, CLSA favored CDMOs, expecting them to outperform CROs in terms of earnings visibility due to better capacity locking capabilities and longer-term projects. The top picks in the global CRO/ CDMO sector remained WUXI APPTEC (02359.HK), WUXI BIO (02269.HK), PHARMARON (03759.HK), Lonza Group (LZAGY.US), and Samsung Biologics, all rated as Outperform. The target prices for WUXI APPTEC, WUXI BIO, and PHARMARON were HKD143.4, HKD48.5, and HKD28.8, respectively. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
